NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$3.04▼ 0.65% ($0.02)today

As of 11:29 AM ET

52-week

$2.23$5.38

Market cap

$123.11M

P/E

-0.87

EPS (TTM)

-$1.18

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$3.04

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 7.71%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 3:29 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 22, 2026, 3:29 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 16.09%FCF (TTM): 18.95%

What changed

The stock rose 16.09% over the last year. Free cash flow grew 18.95% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.

What would invalidate this read

If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer.

CEONicholas A. Saccomano

SectorHealthcare

IndustryBiotechnology

Employees45

IPO dateApr 8, 2021

https://onkuretherapeutics.com

Market multiples

Forward P/E—

EV/EBITDA0.33

Enterprise value-$19.3M

Stock splits

Oct 7, 2024↓ Reverse

Every 10 shares became 1

-90%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-46.91%▲27.5ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲360.53%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.36 · Revenue est $166.67K

View

NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$3.04▼ 0.65% ($0.02)today

As of 11:29 AM ET

52-week

$2.23$5.38

Market cap

$123.11M

P/E

-0.87

EPS (TTM)

-$1.18

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$3.04

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 7.71%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 3:29 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 22, 2026, 3:29 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 16.09%FCF (TTM): 18.95%

What changed

The stock rose 16.09% over the last year. Free cash flow grew 18.95% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.

What would invalidate this read

If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer.

CEONicholas A. Saccomano

SectorHealthcare

IndustryBiotechnology

Employees45

IPO dateApr 8, 2021

https://onkuretherapeutics.com

Market multiples

Forward P/E—

EV/EBITDA0.33

Enterprise value-$19.3M

Stock splits

Oct 7, 2024↓ Reverse

Every 10 shares became 1

-90%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-46.91%▲27.5ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲360.53%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.36 · Revenue est $166.67K

View